Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OMS 527

Drug Profile

OMS 527

Alternative Names: OMS-182399; OMS527; PDE7 inhibitor - Omeros; Type 7 cyclic nucleotide phosphodiesterase inhibitor - Omeros

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asubio Pharma
  • Developer National Institute on Drug Abuse; Omeros Corporation; The Parkinsons Institute and Clinical Center
  • Class Antiparkinsonians; Drug withdrawal therapies; Small molecules
  • Mechanism of Action Type 7 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Substance-related disorders
  • Preclinical Impulse control disorders
  • No development reported Movement disorders

Most Recent Events

  • 16 Sep 2019 Safety and pharmacokinetics data from a phase I trial in Substance-related disorders released by Omeros Corporation
  • 16 Sep 2019 Omeros plans a clinical trial for Substance-related disorders
  • 09 Aug 2019 Omeros Corporation completes a phase I trial in Substance-related disorders (In volunteers) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top